Board of Trustees of The Leland Stanford Junior University Sells 264,273 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

Board of Trustees of The Leland Stanford Junior University decreased its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 76.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 79,740 shares of the company’s stock after selling 264,273 shares during the period. Alto Neuroscience comprises approximately 0.1% of Board of Trustees of The Leland Stanford Junior University’s holdings, making the stock its 14th largest position. Board of Trustees of The Leland Stanford Junior University’s holdings in Alto Neuroscience were worth $912,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers purchased a new position in Alto Neuroscience during the 2nd quarter valued at about $113,000. Federated Hermes Inc. grew its position in shares of Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after buying an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Alto Neuroscience in the 2nd quarter worth approximately $252,000. Bowie Capital Management LLC purchased a new position in shares of Alto Neuroscience in the 2nd quarter worth approximately $462,000. Finally, Zimmer Partners LP purchased a new position in shares of Alto Neuroscience in the 1st quarter worth approximately $1,151,000.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ANRO shares. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Stock Down 4.7 %

Shares of NYSE ANRO opened at $4.27 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience, Inc. has a 12 month low of $3.61 and a 12 month high of $24.00. The company has a 50 day simple moving average of $9.13 and a two-hundred day simple moving average of $11.08.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05. As a group, research analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.